Literature DB >> 26113600

15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas.

Samuel M O'Toole1, Judit Dénes1, Mercedes Robledo1, Constantine A Stratakis1, Márta Korbonits2.   

Abstract

The combination of pituitary adenomas (PA) and phaeochromocytomas (phaeo) or paragangliomas (PGL) is a rare event. Although these endocrine tumours may occur together by coincidence, there is mounting evidence that, in at least some cases, classical phaeo/PGL-predisposing genes may also play a role in pituitary tumorigenesis. A new condition that we termed '3Pas' for the association of PA with phaeo and/or PGL was recently described in patients with succinate dehydrogenase mutations and PAs. It should also be noted that the classical tumour suppressor gene, MEN1 that is the archetype of the PA-predisposing genes, is also rarely associated with phaeos in both mice and humans with MEN1 defects. In this report, we review the data leading to the discovery of 3PAs, other associations linking PAs with phaeos and/or PGLs, and the corresponding clinical and molecular genetics.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  SDH; paraganglioma; pathogenesis; phaeochromocytoma; pituitary

Mesh:

Substances:

Year:  2015        PMID: 26113600     DOI: 10.1530/ERC-15-0241

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  12 in total

1.  Malignant paraganglioma and somatotropinoma in a patient with germline SDHB mutation-genetic and clinical features.

Authors:  Ana Saavedra; Jorge Lima; Lígia Castro; Roberto Silva; Sofia Macedo; Elisabete Rodrigues; Davide Carvalho
Journal:  Endocrine       Date:  2018-08-28       Impact factor: 3.633

Review 2.  Genetics of Cushing's Syndrome.

Authors:  Laura C Hernández-Ramírez; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

Review 3.  The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.

Authors:  Paraskevi Xekouki; Ana Brennand; Ben Whitelaw; Karel Pacak; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2018-10-01       Impact factor: 2.936

Review 4.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04

5.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

Review 6.  The genetic background of acromegaly.

Authors:  Mônica R Gadelha; Leandro Kasuki; Márta Korbonits
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Pituitary Carcinoma in a Patient with an SDHB Mutation.

Authors:  Nicola Tufton; Federico Roncaroli; Irene Hadjidemetriou; Mary N Dang; Judit Dénes; Leonardo Guasti; Maria Thom; Michael Powell; Stephanie E Baldeweg; Naomi Fersht; Márta Korbonits
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

8.  Pheochromocytoma, paragangliomas, and pituitary adenoma: An unusual association in a patient with an SDHD mutation. Case report.

Authors:  Annie Lemelin; Marion Lapoirie; Juliette Abeillon; Hélène Lasolle; Sophie Giraud; Pierre Philouze; Philippe Ceruse; Gérald Raverot; Alain Vighetto; Françoise Borson-Chazot
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

9.  Identification of a TMEM127 variant in a patient with paraganglioma and acromegaly.

Authors:  Beryl Stütz; Marta Korbonits; Karl Kothbauer; Werner Müller; Stefan Fischli
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-09-23

10.  Familial Acromegaly and Bilateral Asynchronous Pheochromocytomas in a Female Patient With a MAX Mutation: A Case Report.

Authors:  Elizaveta Mamedova; Evgeny Vasilyev; Vasily Petrov; Svetlana Buryakina; Anatoly Tiulpakov; Zhanna Belaya
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-31       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.